3,198 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by BDF Gestion

BDF Gestion purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,198 shares of the company’s stock, valued at approximately $1,670,000.

A number of other institutional investors have also added to or reduced their stakes in IDXX. Aurora Investment Managers LLC. purchased a new stake in IDEXX Laboratories in the 2nd quarter worth $2,442,000. National Pension Service lifted its position in shares of IDEXX Laboratories by 5.6% in the second quarter. National Pension Service now owns 129,305 shares of the company’s stock worth $68,071,000 after buying an additional 6,885 shares in the last quarter. NewEdge Advisors LLC boosted its stake in IDEXX Laboratories by 60.9% during the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock valued at $8,552,000 after buying an additional 5,761 shares during the last quarter. Arizona State Retirement System boosted its stake in IDEXX Laboratories by 4.9% during the second quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock valued at $11,988,000 after buying an additional 1,074 shares during the last quarter. Finally, SVB Wealth LLC boosted its stake in IDEXX Laboratories by 17.4% during the first quarter. SVB Wealth LLC now owns 7,335 shares of the company’s stock valued at $4,121,000 after buying an additional 1,089 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.79% of the stock is owned by insiders.

Analysts Set New Price Targets

IDXX has been the subject of several research analyst reports. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. KeyCorp assumed coverage on IDEXX Laboratories in a report on Monday, October 12th. They set a “sector weight” rating on the stock. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. JPMorgan Chase & Co. lowered their target price on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research report on Friday. Finally, The Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a report on Friday. They issued a “buy” rating and a $740.00 target price for the company. Seven analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $744.09.

IDEXX Laboratories Trading Down 0.6%

Shares of NASDAQ:IDXX traded down $3.13 during trading on Monday, reaching $557.23. The company’s stock had a trading volume of 155,436 shares, compared to its average volume of 568,739. The stock has a market capitalization of $43.90 billion, a PE ratio of 39.19, a price-to-earnings-growth ratio of 2.99 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $500.61 and a 12 month high of $769.98. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm’s 50 day simple moving average is $534.22 and its two-hundred day simple moving average is $551.80.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same period in the previous year, the firm posted $3.50 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.